Zevra Therapeutics has reinforced clinical confidence in its orphan drug MIPLYFFA through promising Phase 2/3 data, underscoring its potential to address Niemann-Pick Disease Type C. The company faces significant regulatory uncertainty after a negative European Medicines Agency opinion on Arimoclomol, which it is actively appealing, delaying EU market access. In the U.S., Zevra navigates complex Medicaid Drug Rebate Program obligations that could impact margins and cash flow timing. Despite these challenges, a strong cash position and liquidity provide operational flexibility to support ongoing R&D and commercial scaling efforts.